Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by LeMaitre Vascular in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: LeMaitre Vascular’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333762
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Gross profit | 50,764 | 44,974 | 99,160 | 86,394 |
| Sales and marketing | 14,408 | 14,895 | 28,923 | 29,107 |
| General and administrative | 11,110 | 10,396 | 23,156 | 20,883 |
| Research and development | 4,847 | 3,541 | 8,907 | 7,636 |
| Total operating expenses | 30,365 | 28,832 | 60,986 | 57,626 |
| Income from operations | 20,399 | 16,142 | 38,174 | 28,768 |
| Other income (expense): | ||||
| Investment income | 3,386 | 2,980 | 6,710 | 5,883 |
Item 1. Financial Statements
FAQ
- What is LeMaitre Vascular's R&D?
- LeMaitre Vascular (LMAT) reported R&D of $4.85M in Q2 2026.
- How has LeMaitre Vascular's R&D changed year-over-year?
- LeMaitre Vascular's R&D increased by 36.9% year-over-year, from $3.54M to $4.85M.
- What is the long-term trend for LeMaitre Vascular's R&D?
- Over 4 years (2021 to 2025), LeMaitre Vascular's R&D has grown at a 4.6% compound annual growth rate (CAGR), from $11.8M to $14.14M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about LeMaitre Vascular's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude